In order to routinely apply dPCR for BCR‐ABL1 detection and quantification for a personalized management of CML patients, other efforts have to be performed in the standardization of the procedures and in the alignment of the results generated by the different dPCR platforms.22, 24, 41. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.